ICER’s Biopharma Members: Why They Joined And What They Get
Executive Summary
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
You may also be interested in...
ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
ICER Faces New Foe As Patient, Disability Alliance Takes Aims At Reports On Mayzent, Spravato
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.